Efficiency of interferon-free therapy regimens in patients with chronic hepatitis C
- Authors: Makashova V.V1, Ponezheva Z.B1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human WellBeing
- Issue: No 6 (2017)
- Pages: 31-34
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278693
- ID: 278693
Cite item
Open Access
Access granted
Abstract
The paper gives data on the efficiency of interferon-free antiviral therapy regimens in patients with chronic hepatitis C. It analyzes the literature sources containing the results of clinical trials of different treatment regimens, clinical practice guidelines, as well as the existing opportunities and prospects of current treatments in primary patients and patients unresponsive to the standard antiviral therapy.
Full Text
About the authors
V. V Makashova
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human WellBeing
Email: veramakashova@yandex.ru
MD; Leading Researcher 3a, Novogireevskaya St., Moscow 111123, Russia Telephone: +7(495) 365-05-90
Zh. B Ponezheva
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human WellBeing
Email: doktorim@mail.ru
MD; Leading Researcher, Clinical Department of Infectious Diseases Moscow
References
- Chulanov V., Zhdanov K., Kersey K., Zhu Y., Svarovskaуa E., Massetto B., et al. Sofosbuvir plus Ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 Infection. Hepatology 2014; 60(Suppl 1): 676A.
- Рекомендации по диагностике и лечению взрослых больных гепатитом С. М., 2014. 91 с. DOI: http://arvt.ru/sites/default/files/rf-recom-gep-C-2014.pdf
- Понежева Ж.Б., Семенова И.В. Безинтерфероновая терапия ХГС. Лечащий врач 2017; (2) https://www.lvrach.ru/2017/02/15436659/.
- Ющук Н.Д, Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты. Клиника, диагностика, лечение. 2-е изд. М.: ГЭОТАР-Медиа, 2015. 302 с.
- EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. 2017; 66: 153-94.
- Recommendations for Testing, Managing, and Treating Hepatitis C. Changes made April 12, 2017. http://www.hcvguidelines.org
- Bourliere M., Sukowski M.S., Omata M. et al. An intergratted salety and efficacy analysis of > 500 pacients with compensated cirhosis treated with lediprasvir/sofosbuvir with orwithout ribaviri. Hepatology 2014; 60: 239A.
- Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370(20): 1879-88.
- Welzel T., Petersen J., Herzer K., Ferenci P., Gschwantler M., Cornberg M., et al. Daclatasvir plus sofosbuvir with or without ribavirin for treatment of chronic HCV infection in patients with advanced liver disease: results of a European compassionate use program. J. Hepatol. 2016; 64 (Suppl 2): S825.
- Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Rajender R.K., Hassanein T., Jacobson et al. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. N. Engl. J. Med. 2014; 370: 211-21
Supplementary files
